Literature DB >> 2885642

Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever.

J C Clegg, G Lloyd.   

Abstract

The Lister strain of vaccinia virus was used to construct a recombinant that expressed the nucleocapsid gene of Lassa virus. Guineapigs immunised with the recombinant virus were protected against challenge with Lassa virus, whereas control animals showed the usual disease course, including pyrexia, anorexia, viraemia, and death. These data indicate not only that protective immunity to Lassa fever can be evoked by an experimental vaccine, but also that this response can be mediated by an internal protein component of the virus.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2885642     DOI: 10.1016/s0140-6736(87)90767-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  37 in total

1.  Mucosal immunization with Salmonella typhimurium expressing Lassa virus nucleocapsid protein cross-protects mice from lethal challenge with lymphocytic choriomeningitis virus.

Authors:  M Djavani; C Yin; I S Lukashevich; J Rodas; S K Rai; M S Salvato
Journal:  J Hum Virol       Date:  2001 Mar-Apr

2.  Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man.

Authors:  Juan C Zapata; Maria S Salvato
Journal:  Future Virol       Date:  2015-03-13       Impact factor: 1.831

3.  Arenavirus Genome Rearrangement for the Development of Live Attenuated Vaccines.

Authors:  Benson Yee Hin Cheng; Emilio Ortiz-Riaño; Juan Carlos de la Torre; Luis Martínez-Sobrido
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

4.  Epitope mapping of the Lassa virus nucleoprotein using monoclonal anti-nucleocapsid antibodies.

Authors:  F T Hufert; W Lüdke; H Schmitz
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

5.  Identification of protective Lassa virus epitopes that are restricted by HLA-A2.

Authors:  Jason Botten; Jeff Alexander; Valerie Pasquetto; John Sidney; Polly Barrowman; Joey Ting; Bjoern Peters; Scott Southwood; Barbara Stewart; Maria P Rodriguez-Carreno; Bianca Mothe; J Lindsay Whitton; Alessandro Sette; Michael J Buchmeier
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

6.  Common antiviral cytotoxic t-lymphocyte epitope for diverse arenaviruses.

Authors:  M B Oldstone; H Lewicki; D Homann; C Nguyen; S Julien; J E Gairin
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

Review 7.  VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.

Authors:  Pierre Leblanc; Leonard Moise; Cybelle Luza; Kanawat Chantaralawan; Lynchy Lezeau; Jianping Yuan; Mary Field; Daniel Richer; Christine Boyle; William D Martin; Jordan B Fishman; Eric A Berg; David Baker; Brandon Zeigler; Dale E Mais; William Taylor; Russell Coleman; H Shaw Warren; Jeffrey A Gelfand; Anne S De Groot; Timothy Brauns; Mark C Poznansky
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 8.  Epidemiology and Management of the 2013-16 West African Ebola Outbreak.

Authors:  M L Boisen; J N Hartnett; A Goba; M A Vandi; D S Grant; J S Schieffelin; R F Garry; L M Branco
Journal:  Annu Rev Virol       Date:  2016-08-15       Impact factor: 10.431

Review 9.  The search for animal models for Lassa fever vaccine development.

Authors:  Igor S Lukashevich
Journal:  Expert Rev Vaccines       Date:  2013-01       Impact factor: 5.217

10.  Imported lassa fever in Germany: molecular characterization of a new lassa virus strain.

Authors:  S Günther; P Emmerich; T Laue; O Kühle; M Asper; A Jung; T Grewing; J ter Meulen; H Schmitz
Journal:  Emerg Infect Dis       Date:  2000 Sep-Oct       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.